Logo image
Sign in
Survival Data from a Phase II, Open-Label Study of Pazopanib Or Lapatinib Monotherapy in Patients with Advanced and Recurrent Cervical Cancer
Journal article

Survival Data from a Phase II, Open-Label Study of Pazopanib Or Lapatinib Monotherapy in Patients with Advanced and Recurrent Cervical Cancer

Bradley J. Monk and L. N. Pandite
Journal of Clinical Oncology, Vol.29(36), p.4545
2011

Metrics

4 Record Views

Details